Study #2019-0125
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study To Evaluate The Safety And Efficacy Of Alpha-1 Antitrypsin For The Prevention Of Graft-Versus Host Disease In Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
MD Anderson Study Status
Not Accepting
Treatment Agent
AAT, Placebo
Description
This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing an unrelated (matched or single allele mismatched) or matched related allogeneic hematopoietic cell transplantation (HCT).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute-graft-versus-host Disease
Study phase:
Phase II/III
Physician name:
Amin Alousi
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-844-794-1615
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.